The total return over the past 12 months is +499.53% vs. +16.94% for the S&P 500. So far it's up +418.32% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +499.53% | +50.14% | (11.55%) | +5.84% | (12.28%) | N/A |
| Total Return CAGR | +499.53% | +50.14% | (11.55%) | +5.84% | (12.28%) | N/A |
| Revenue CAGR | +34.55% | +1008.79% | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Iovance Biotherapeutics, Inc. (IOVA)
| Year | Start price | End price | IOVA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.73 | $14.15 | +418.32% | +14.51% | +403.81% |
| 2025 | $7.40 | $2.73 | (63.11%) | +17.72% | (80.83%) |
| 2024 | $8.13 | $7.40 | (8.98%) | +24.89% | (33.87%) |
| 2023 | $6.39 | $8.13 | +27.23% | +26.19% | +1.04% |
| 2022 | $19.09 | $6.39 | (66.53%) | (18.17%) | (48.36%) |
| 2021 | $46.40 | $19.09 | (58.86%) | +28.74% | (87.60%) |
| 2020 | $27.68 | $46.40 | +67.63% | +18.37% | +49.26% |
| 2019 | $8.85 | $27.68 | +212.77% | +31.22% | +181.55% |
| 2018 | $8.00 | $8.85 | +10.63% | (4.56%) | +15.19% |
| 2017 | $6.95 | $8.00 | +15.11% | +21.70% | (6.59%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
